What quantum sensing actually means
Quantum sensors use properties such as coherence, spin states or quantum interference to measure physical quantities. Some technologies in this broad family are mature: superconducting quantum interference devices have long been used in magnetoencephalography. Newer platforms include optically pumped magnetometers and nitrogen-vacancy centres in diamond. A 2023 Nature Reviews Physics article describes promising biomedical applications while explicitly discussing the path from laboratory performance to commercialization. [1]
The word quantum does not establish clinical novelty or superiority. MRI and conventional MEG already rely on quantum physics. For a new sensor, the relevant questions are what quantity it measures, at what accuracy and stability, in which specimen or patient, and whether the result improves a clinical decision. Sensitivity measured under laboratory conditions is not equivalent to diagnostic sensitivity in a diverse patient population.
- Distinguish the physical sensor from downstream signal processing.
- Report units, limit of detection, dynamic range and calibration.
- Avoid using quantum as a proxy for clinical validation.
Wearable brain sensing is a real technical advance
Optically pumped magnetometers can detect weak magnetic fields without the cryogenic cooling required by conventional superconducting MEG sensors. In 2018, researchers demonstrated a wearable OPM-MEG system that recorded brain activity at millisecond resolution while participants moved, including during head movement and ball play. [2] This is an important engineering demonstration because rigid scanners limit movement and fit.
Clinical translation still requires comparison with established methods, reproducibility, shielding and motion management, age-appropriate hardware, trained interpretation and evidence for a defined indication. Potential value in children, pregnancy or movement disorders should be treated as a research question until performance and patient outcomes are established in those populations.
- Established: OPMs can measure biomagnetic signals in human research settings.
- Emerging: wearable arrays may broaden who can be studied and during what tasks.
- Unproven: routine diagnostic superiority for a specific women's health condition.
Diamond sensors operate closer to cells than clinics
Nitrogen-vacancy centres in diamond can sense magnetic fields, temperature and other local physical properties at very small scales. Reviews describe experiments involving neurons, cells, proteins and magnetic biomarkers, sometimes under ambient conditions. [1][3] These capabilities may support basic research into cellular processes or future assays.
The translational distance is substantial. Biological matrices can introduce noise and nonspecific interactions. Manufacturing consistency, sensor functionalization, sample preparation, reference standards and clinical cutoffs require validation. A signal associated with a hormone or disease in a laboratory does not become a diagnostic test until analytical performance, clinical validity and clinical utility are demonstrated.
- Require blinded testing on clinically representative specimens.
- Compare against an appropriate reference method.
- Report false positives, false negatives and failed measurements.
- Assess biocompatibility when materials contact tissue or cells.
Women's health use cases need disciplined selection
Potential areas include fetal magnetocardiography, low-field magnetic measurements, cellular metabolomics and high-sensitivity biomarker assays. NIH has identified quantum-enabled sensing and imaging as a translational research opportunity and cites biomagnetic applications such as pediatric epilepsy and fetal cardiac arrhythmia. [4] This signals research priority, not regulatory approval or standard care.
A valuable use case should address a limitation that conventional technologies cannot adequately solve, such as movement restriction, poor spatial fit or insufficient sensitivity for a validated biomarker. It should also fit the care environment. A sensor that requires exceptional magnetic shielding, specialist calibration or complex sample handling may not improve access even if its laboratory sensitivity is impressive.
- Define the unmet need and current reference test.
- Specify the decision that a more sensitive measurement would change.
- Model cost, maintenance, training and workflow before a clinical trial.
- Include pregnant people only under an appropriate safety and ethics protocol.
A translation pathway from signal to outcome
The IMDRF clinical evaluation framework is useful even when the underlying physics is novel. First establish a valid association between the measured signal and the clinical condition. Then show that the system processes inputs accurately and reliably. Finally demonstrate clinical performance in the intended population and setting. [5] Reporting should include calibration drift, environmental interference and uncertainty.
If software or AI interprets the sensor output, the combined system requires lifecycle governance. WHO's AI principles call for autonomy, safety, transparency, accountability, equity and sustainability. [6] The strongest horizon scan therefore labels each claim as established, emerging or investigational and changes that label only when new evidence meets a predefined threshold.
- Analytical validity precedes diagnostic accuracy.
- Diagnostic accuracy precedes evidence of clinical utility.
- Clinical utility does not automatically establish cost-effectiveness or equitable access.
- Regulatory status should be verified for the exact system and intended use.
What the evidence cannot yet answer
- Many quantum-sensing publications are physics or engineering demonstrations rather than clinical trials.
- Performance in controlled laboratories may not survive motion, biological variability or routine workflow.
- Quantum sensing, quantum dots and quantum computing are distinct technologies and should not be conflated.
- No general claim of improved women's health outcomes can be made from current platform-level evidence.
Questions worth taking into care
- What physical quantity is measured and why is it clinically meaningful?
- Has analytical performance been replicated outside the developer's laboratory?
- Was diagnostic accuracy tested prospectively in the intended population?
- Does the result change management or improve a patient-important outcome?
- What shielding, calibration, training and maintenance are required?
Source record
Evidence used in this review
Sources were selected for clinical authority, methodological relevance and traceability. Links open the original guidance, public-health record or research publication.
- [1]Quantum sensors for biomedical applications
Nature Reviews Physics · 2023
- [2]
- [3]Recent Developments of Nanodiamond Quantum Sensors for Biological Applications
Advanced Science · 2022
- [4]Quantum-enabled Approaches to Advance Biomedical Applications
National Center for Advancing Translational Sciences · 2024
- [5]Software as a Medical Device
U.S. Food and Drug Administration · 2025
- [6]Ethics and governance of artificial intelligence for health
World Health Organization · 2021
This evidence synthesis is for general information. It does not diagnose a condition or replace care from a qualified health professional. Treatment choices depend on individual history, examination, local guidance and informed preference. Emergency or rapidly worsening symptoms need urgent local medical assessment.



